NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced the release of a white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” which outlines how its investigational platform aims to overcome key barriers to commercializing brain-delivered therapeutics. The white paper, available on the Scientific Resources section of nmtc1.com, emphasizes the growing demand for efficient, reproducible methods of delivering cell and gene therapies, biologics, and other central nervous system (CNS) therapeutics directly to the brain.
Convection-enhanced delivery (CED) has shown promise in bypassing the blood-brain barrier and achieving targeted drug distribution, but current approaches may present challenges as therapies move toward broader commercial use. The StereoCED™ platform is being designed to integrate with robotic stereotactic systems already common in neurosurgical operating rooms, enabling simultaneous, multi-trajectory intracranial drug delivery through a streamlined workflow. This approach could significantly reduce procedure time compared to traditional methods that may require lengthy sequential infusions lasting 8 to 12 hours.
“Brain-delivered therapeutics are approaching an important inflection point,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”
The announcement comes as the field of CNS drug delivery sees rapid advancement, with potential implications for patients suffering from neurological disorders. If successful, the StereoCED™ platform could enable more hospitals to offer these cutting-edge therapies by removing procedural bottlenecks, potentially increasing access for patients. The platform is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization.
NeuroOne, based in Eden Prairie, Minnesota, markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information is available at nmtc1.com.
The white paper highlights the potential for StereoCED™ to address scalability, a critical factor as the industry prepares for broader adoption of brain-targeted therapies. By leveraging existing robotic systems, the platform aims to reduce the need for specialized workflows, making it easier for healthcare systems to adopt. Device availability for research and investigational studies is expected by the end of the fiscal year.
